

Asia Pacific In-Vitro Diagnostics Market to Surpass at a Valuation of US\$ 23.01 Billion By 2031

CHICAGO, UNITED STATES, July 17, 2023

/EINPresswire.com/ -- The [Asia Pacific In-Vitro Diagnostics Market](#) is estimated to reach US\$ 23.01 billion by 2031, up from US\$ 10.5 billion in 2021, growing at a CAGR of 10.5% during the forecast period from 2021-2031.

For more information, contact astute@astuteanalytics.com or visit <https://www.astuteanalytics.com/request-sample/asia-pacific-in-vitro-diagnostics-market>

Due to the increased frequency of chronic diseases, the adoption of new diagnostic technologies, and the rising demand for accurate and reliable diagnostic tests, the Asia Pacific in-vitro diagnostics market is anticipated to expand. Due to intense market competition, the leading businesses are working hard to commercialize IVD products on a broad scale and enhance diagnostic capabilities globally.

The need for IVD testing has increased in the Asia Pacific region due to the high prevalence of chronic diseases like diabetes, heart disease, and cancer. By 2030, 578 million people in the Asia Pacific region are likely to have diabetes, up from a projected 463 million in 2021, according to the International Diabetes Federation. Cancer. According to a study by the International Agency for Study on Cancer, about half of all new cancer cases globally are attributed to the Asia Pacific in-vitro diagnostics business.

The IVD market is rising by the prevalence of infectious diseases in the Asia Pacific, including hepatitis, TB, and HIV. For instance, China has a sizable incidence of hepatitis B and C, while India has the highest burden of tuberculosis globally, with an expected 2.44 million cases in 2022. Diagnostics are an essential part of the IVD market in the region since they play a key role in disease identification, treatment monitoring, and reducing the spread of infectious diseases.

The market is also growing with new diagnostics categories developments, AI-assisted radiology usage, and sophisticated robotics technology. Due to less invasiveness and the ability to locate,



identify, and help treat lung nodules (such as through surgical extraction), recent developments in robotics-assisted endoscopy provide intriguing alternatives to conventional methods. Consequently, advancements in robots that enable minimally invasive tissue selection and AI-assisted imaging analysis will help maximize disease identification, even in the case of early-stage and difficult cancer types.

Chemical reagents and ELISA kits are also crucial market elements.

The reagents and instruments segment generated major sales of over 93%, which combined account for the majority of the market's growth in the Asia Pacific region. These parts provide a wide range of diagnostic options, including mass spectrometers for biomolecule analysis, immunoassay analyzers for detecting antibodies and antigens, and PCR machines for diagnosing genetic and viral diseases. Chemical reagents and ELISA kits are also crucial market elements.

The demand for enhanced diagnostic tools and methods is also rising by the increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders in the Asia Pacific in-vitro diagnostics market. According to the 2021 International Diabetes Federation (IDF) report, the number of diabetics in Southeast Asia is expected to rise by 68% by 2045, reaching 152 million people, and the Western Pacific region has the third highest prevalence of diabetes in the world (11.9%).

Immunodiagnosics is likely to dominate the IVD market in the Asia Pacific with a 29% market share.

Immunodiagnosics is likely to dominate the IVD market in the Asia Pacific with a 29% market share. The need for quick and accurate diagnosis and the increasing prevalence of infectious and chronic diseases are factors in this expansion. Antibodies are an increasingly prominent method in the field of immunodiagnosics for locating antigens in patient samples.

In-Vitro Diagnostics Finds Major Application in Infectious Disease Treatment

The infectious disease diagnostics segment captures about 49% of the market revenue share. This market is expanding owing to the increasing prevalence of infectious disorders such as COVID-19, hepatitis, and tuberculosis. A rising understanding of the significance of early and precise identification of infectious diseases is also present in the region.

The Asia Pacific region's in-vitro diagnostics (IVD) market is composed of both huge corporations with several business lines and smaller but specialized rivals.

The Asia Pacific region's in-vitro diagnostics (IVD) market is composed of both huge corporations with several business lines and smaller but specialized rivals. Roche Diagnostics, Sysmex Corporation, Abbott Laboratories, and Siemens Healthineers are the top APAC in-vitro diagnostics market businesses. These companies are consistently developing cutting-edge IVD technologies, diversifying their product lines, and investing in R&D in order to maintain their market position.

आपको यह जानकारी चाहिए- <https://www.astuteanalytica.com/industry-report/asia-pacific-in-vitro-diagnostics-market>

According to Astute Analytica's report, the IVD market in the Asia Pacific region is oligopolistic. A limited number of businesses dominate the market, with the top 5 players holding more than 63% of the total market share. The level of competition is not very variable as a result of the significant market concentration.

प्रमुख कम्पनियाँ

- Abbott
- Agilent Technologies, Inc.
- Becton Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc
- Charles River Laboratories
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Qiagen
- Quest Diagnostics
- Quidel Corp.
- Siemens Healthineers
- Sysmex Corp.
- Other Prominent Players

प्रमुख उत्पाद

इस रिपोर्ट में, हम आपको एशिया-पैसिफिक क्षेत्र में IVD बाजार की प्रमुख कम्पनियों के बारे में जानकारी देंगे & उनके उत्पादों, सेवाओं, बाजारों, और अन्य जानकारी.

हम आपको & आपको

- Reagents
- Instruments
- Software
- Services

हम आपको

- Immunodiagnostics
- Hematology
- Molecular Diagnostics
- Tissue Diagnostics
- Clinical Chemistry

- Others

□□ □□□□□□□□□□

- Cancer diagnostics
- Blood glucose monitoring
- Human genetic testing
- Immunoassays
- Hepatitis tests
- Infectious Diseases diagnostics
- Cardiac Diseases
- Nephrological Diseases
- Gastrointestinal Diseases
- Others

□□ □□□-□□□□

- Standalone Laboratories
- Hospitals
- Academic And Medical Schools
- Point Of Care
- Others

□□ □□□□□□

- India
- Japan
- South Korea
- Australia & New Zealand
- ASEAN
- Rest of Asia Pacific

□□□□□□□□ □□□□□□□ □□□□□□ □□□□ □□ □□□□□□□□□□ □□□□□□@-

<https://www.astuteanalytica.com/request-sample/asia-pacific-in-vitro-diagnostics-market>

□□□□□ □□□□□□ □□□□□□□□□□:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is

possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg

Astute Analytica

+1 888-429-6757

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/644804418>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.